Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.

[1]  Sebastian D. Mackowiak,et al.  Selective Mediator-dependence of cell type-specifying transcription , 2020, Nature Genetics.

[2]  James M. Bogenberger,et al.  Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia , 2019, Front. Oncol..

[3]  S. Fawell,et al.  AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells , 2019, Clinical Cancer Research.

[4]  Yan Fan,et al.  Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. , 2019, European journal of medicinal chemistry.

[5]  J. Zeidner,et al.  Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach , 2019, Expert opinion on investigational drugs.

[6]  Michael J. Emanuele,et al.  Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer , 2019, Science Signaling.

[7]  N. Hannett,et al.  Pol II phosphorylation regulates a switch between transcriptional and splicing condensates , 2019, Nature.

[8]  E. Dmitrovsky,et al.  Abstract 4407: Next generation CDK2/9 inhibitor CYC065 triggers anaphase catastrophe in diverse aneuploid cancers and markedly inhibits growth and metastasis , 2019, Molecular and Cellular Biology / Genetics.

[9]  David A. Orlando,et al.  Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo , 2019 .

[10]  L. Drew,et al.  Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma , 2019, Molecular Cancer Therapeutics.

[11]  A. Chinnaiyan,et al.  Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer , 2019, Nature.

[12]  Charles Y. Lin,et al.  Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. , 2019, Cell chemical biology.

[13]  Christina S. Leslie,et al.  FOXA1 mutations alter pioneering activity, differentiation, and prostate cancer phenotypes , 2019, Nature.

[14]  Veronika A. Herzog,et al.  Quantification of experimentally induced nucleotide conversions in high-throughput sequencing datasets , 2019, BMC Bioinform..

[15]  Vincent L. Butty,et al.  Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription. , 2019, Cell chemical biology.

[16]  Henry W. Long,et al.  ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. , 2019, Cancer cell.

[17]  Christopher J. Ott,et al.  Small-molecule targeting of brachyury transcription factor addiction in chordoma , 2019, Nature Medicine.

[18]  Lindsey A. Marsh,et al.  Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer , 2018, Oncotarget.

[19]  C. Zahnow,et al.  Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer , 2018, Cell.

[20]  P. Nelson,et al.  Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer , 2018, The Journal of clinical investigation.

[21]  Charles H. Li,et al.  Mediator and RNA polymerase II clusters associate in transcription-dependent condensates , 2018, Science.

[22]  T. Sellers,et al.  MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species , 2018, Translational research : the journal of laboratory and clinical medicine.

[23]  Jesse J. Lipp,et al.  SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis , 2018, Science.

[24]  A. Giordano,et al.  CDK9 inhibitors in acute myeloid leukemia , 2018, Journal of experimental & clinical cancer research : CR.

[25]  A. Giordano,et al.  CDK9: A key player in cancer and other diseases , 2018, Journal of cellular biochemistry.

[26]  Simak Ali,et al.  CT7001, a Novel Orally Bio-Available CDK7 Inhibitor, Is Highly Active in in-Vitro and in-Vivo Models of AML , 2017 .

[27]  R. Young,et al.  Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. , 2017, Nature chemical biology.

[28]  Daniel S. Day,et al.  YY1 Is a Structural Regulator of Enhancer-Promoter Loops , 2017, Cell.

[29]  H. Briem,et al.  Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer , 2017, ChemMedChem.

[30]  Johannes Zuber,et al.  Thiol-linked alkylation of RNA to assess expression dynamics , 2017, Nature Methods.

[31]  Nicholas A. Sinnott-Armstrong,et al.  An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues , 2017, Nature Methods.

[32]  Christopher J. Ott,et al.  BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. , 2017, Molecular cell.

[33]  D. Bearss,et al.  Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib , 2017 .

[34]  P. Roberts,et al.  Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors , 2017, Oncotarget.

[35]  R. Young,et al.  Transcriptional Addiction in Cancer , 2017, Cell.

[36]  Neville E. Sanjana,et al.  Transcription control by the ENL YEATS domain in acute leukemia , 2016, Nature.

[37]  N. Hannett,et al.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. , 2016, Nature chemical biology.

[38]  S. Schreiber,et al.  Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile. , 2016, ACS chemical biology.

[39]  T. Gonda,et al.  CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression , 2016, Oncotarget.

[40]  A. Giordano,et al.  Overview of CDK9 as a target in cancer research , 2016, Cell cycle.

[41]  M. Schweizer,et al.  Persistent androgen receptor addiction in castration-resistant prostate cancer , 2015, Journal of Hematology & Oncology.

[42]  B. Mock,et al.  Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression , 2015, ACS chemical biology.

[43]  Nathan C. Sheffield,et al.  ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors , 2015, Nature Methods.

[44]  C. Evans,et al.  Mechanisms of resistance in castration-resistant prostate cancer (CRPC) , 2015, Translational andrology and urology.

[45]  John T. Lis,et al.  Getting up to speed with transcription elongation by RNA polymerase II , 2015, Nature Reviews Molecular Cell Biology.

[46]  Howard Y. Chang,et al.  ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide , 2015, Current protocols in molecular biology.

[47]  A. Koehler,et al.  Probing Small‐Molecule Microarrays with Tagged Proteins in Cell Lysates , 2014, Current protocols in chemical biology.

[48]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[49]  Darjus F. Tschaharganeh,et al.  CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma , 2014, Genes & development.

[50]  P. Nordlund,et al.  The cellular thermal shift assay for evaluating drug target interactions in cells , 2014, Nature Protocols.

[51]  Yulia Koryakina,et al.  Androgen receptor phosphorylation: biological context and functional consequences. , 2014, Endocrine-related cancer.

[52]  M. Malumbres.  Cyclin-dependent kinases , 2014, Genome Biology.

[53]  Sridhar Ramaswamy,et al.  Targeting transcription regulation in cancer with a covalent CDK7 inhibitor , 2014, Nature.

[54]  Nicolas Stransky,et al.  A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein , 2014, Molecular Cancer Therapeutics.

[55]  T. Thompson,et al.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches , 2013, Oncogene.

[56]  P. Kaldis,et al.  Cdks, cyclins and CKIs: roles beyond cell cycle regulation , 2013, Development.

[57]  P. Nordlund,et al.  Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay , 2013, Science.

[58]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[59]  J. Hoffman-Censits,et al.  Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[60]  P. Unger,et al.  KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation. , 2012, The American journal of pathology.

[61]  J. Wood,et al.  TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties , 2012, Leukemia.

[62]  P. Stattin,et al.  Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival , 2011, PloS one.

[63]  Stuart L. Schreiber,et al.  Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles , 2010, Proceedings of the National Academy of Sciences.

[64]  L. Johnson,et al.  Halogen bonds form the basis for selective P-TEFb inhibition by DRB. , 2010, Chemistry & biology.

[65]  Christopher B. Burge,et al.  c-Myc Regulates Transcriptional Pause Release , 2010, Cell.

[66]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[67]  Stuart L. Schreiber,et al.  A small molecule that binds Hedgehog and blocks its signaling in human cells , 2009, Nature chemical biology.

[68]  Colleen D. McCabe,et al.  Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. , 2009, Cancer research.

[69]  L. Johnson,et al.  The structure of P‐TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation , 2008, The EMBO journal.

[70]  A. Koehler,et al.  Small-molecule microarrays as tools in ligand discovery. , 2008, Chemical Society reviews.

[71]  Y. Ohkuma,et al.  Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. , 2007, Journal of biochemistry.

[72]  Stuart L Schreiber,et al.  A robust small-molecule microarray platform for screening cell lysates. , 2006, Chemistry & biology.

[73]  M. Serio,et al.  Real-Time RT-PCR for the Measurement of Prostate-Specific Antigen mRNA Expression in Benign Hyperplasia and Adenocarcinoma of Prostate , 2003, Clinical chemistry and laboratory medicine.

[74]  P. Furet,et al.  Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. , 1999, Pharmacology & therapeutics.

[75]  P. Furet,et al.  Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. , 1997, Journal of medicinal chemistry.

[76]  C. Bonne,et al.  Methyltrienolone, a specific ligand for cellular androgen receptors , 1975, Steroids.

[77]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[78]  I. McEwan.  Intrinsic disorder in the androgen receptor: identification, characterisation and drugability. , 2012, Molecular bioSystems.

[79]  Stefan Knapp,et al.  Kinase inhibitor selectivity profiling using differential scanning fluorimetry. , 2012, Methods in molecular biology.